人类微生物组市场规模预计将从 2023 年的 10.7 亿美元增至 2031 年的 48.4 亿美元;预计 2023-2031 年期间市场复合年增长率将达到 20.8%。精准医疗的兴起很可能成为未来几年市场的主要趋势。
人类微生物组市场分析
人体微生物组行业的增长、创新和市场动态受到市场主要参与者投资的极大影响。主要参与者正在投入大量资金进行研发,以创造基于微生物组的新型益生菌、诊断和治疗方法。这些支出刺激了创新,确定了新的菌株、作用方式和药用用途。临床试验获得大量资金,这对于证明基于微生物组的产品的有效性和安全性至关重要。例如,微生物组绘图技术的先驱 Kanvas Biosciences 于 2023 年 6 月宣布了 1200 万美元的 A 轮前融资。该公司的专有平台技术有可能改变与微生物组相关的疾病的药物开发,并将在投资的帮助下得到进一步开发。这些合作伙伴关系使共享资源、专业知识和技术进步变得更加容易,从而加快了产品开发。
此外,Seventure Partners 和 Flagship Pioneering 等知名投资者正在积极资助分析微生物组数据的公司,反映出人们对微生物组在健康中的作用的认识日益加深。因此,对研发的大量投资可能会推动精准医疗和治疗干预的进步,从而为市场创造充足的机会。
人类微生物组市场概览
正在研发的新药、产品开发和增强以及战略合作伙伴关系的增加都是使中国微生物组疗法市场受益的重要因素。领先的人工智能驱动的微生物组治疗公司 Xbiome Inc. 从 Assembly Biosciences, Inc. 手中收购了临床阶段的 M201 项目,后者是一家临床阶段的生物技术公司,致力于开发针对乙肝等病毒性疾病的尖端治疗方法。目标疾病的日益流行预计将推动人类微生物组市场的增长。在中国,未来随着研究不断揭示人类微生物组在各种健康状况中的重要作用,人们对开发基于微生物组的疗法的兴趣日益浓厚。对于胃肠道疾病、自身免疫性疾病和代谢紊乱等疾病尤其如此,因为微生物组对这些疾病的影响是众所周知的。微生物组疗法作为更有效和个性化的治疗方法的潜力为市场扩张提供了一个有希望的机会。根据美国国立卫生研究院 2021 年 6 月发布的统计数据,中国人的肠易激综合征患病率为 2.3–15.8%。
定制此报告以满足您的需求
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
- 获取此报告的关键市场趋势。这个免费样品将包括数据分析,从市场趋势到估计和预测。
人类微生物组市场驱动因素和机遇
政府举措
政府举措和支持计划对人体微生物组市场增长产生了重大影响。政府经常为人体微生物组研究提供大量资金和补助金。这种财政援助加速了新型治疗方法、设备和诊断方法的开发。资金支持人体微生物组领域的初创企业和中小型企业 (SME) 的产品创新和商业化。例如,NIH 启动了一个人体微生物组项目。这个项目可以改变我们理解人类健康的方式,并预防、诊断和治疗各种疾病。作为 NIH 医学研究路线图的一部分,人体微生物组项目将在未来五年内向研究人员提供 1.15 亿美元的奖励。基于微生物组的治疗学是一个蓬勃发展的领域。由于 Seres Therapeutics 的药物 Vowst 最近获批用于治疗艰难梭菌感染,人们对基于微生物组的治疗学的兴趣有所增加。将微生物组益生菌重新归类为药物是一种日益增长的趋势,最近基于微生物组的治疗学的发展可能对此产生了影响。欧盟在将阴道益生菌重新归类为药物方面取得了重大进展。
大力投资研发
人类微生物组具有改变医疗保健行业的潜力,这导致近期研发投资激增。人类微生物组由数以万亿计的细菌、真菌和病毒组成,它们生活在人体内和体表,对身体健康以及疾病的预防和治疗至关重要。基于微生物组的疗法开发正获得生物技术初创公司和制药公司的大量资金。例如,印度首批微生物组初创公司之一 Xome Life Sciences 专注于微生物组的方方面面。该公司正在开发基于微生物组的预后、诊断和治疗工具,帮助人们过上更健康的生活,并就自己的健康做出更好的决定。Seres Therapeutics 最近开发了一种获得 FDA 批准的疗法,用于治疗复发性艰难梭菌感染,这是一种基于微生物组的药物所针对的胃肠道疾病。Vedanta Biosciences 筹集了大量资金,以建立其从微生物组中提取的免疫疗法产品线,用于治疗自身免疫性疾病和癌症。 Seventure Partners 和 Flagship Pioneering 等知名投资者正在积极投资分析微生物组数据的公司,反映出人们对微生物组在健康中的作用的认识日益加深。因此,预计对研发的大量投资将推动精准医疗和治疗干预的进步,从而为市场创造大量机会。
人类微生物组市场报告细分分析
有助于得出人类微生物组市场分析的关键部分是类型、应用、疾病类型和地理位置。
- 人类微生物组市场按类型分为产品、软件和服务。产品部分进一步分为益生菌和益生元。产品部分在 2023 年占据了人类微生物组市场的更大份额,预计在 2023-2031 年期间将实现更高的复合年增长率。
- 根据应用,人类微生物组市场分为治疗、诊断和研究。2023 年,治疗领域占据人类微生物组市场的最大份额。
- 根据疾病类型,人类微生物组市场细分为肥胖症、糖尿病、自身免疫性疾病、癌症、胃肠道疾病等。2023 年,胃肠道疾病占据了人类微生物组市场的最大份额。
人类微生物组市场份额按地区分析
人类微生物组市场报告的地理范围主要分为 5 个主要区域:北美、欧洲、亚太地区、中东和非洲以及南美和中美。北美在 2023 年占据了市场主导地位。北美市场的增长特点是对人类微生物组的研究活动强劲、生物技术资金增加、民众健康意识增强以及对益生菌和益生元治疗慢性病的需求增加。人类微生物组在生物技术领域的应用正在迅速增长;它正在成为治疗各种慢性疾病的重要疗法。美国对基于人类微生物组的疗法的研究和开发显着增长,从而导致私人投资增加和环境微生物组工程的进步。根据 2019 年《自然》杂志发表的一篇文章,在过去十年中,美国对人类微生物组研究的投资最多,约为 10 亿美元。其中约 20% 的资金用于人类微生物组计划 (HMP) 的两个阶段,该计划旨在为研究人类微生物组创造必要的研究资源。HMP 于 2007 年启动,旨在建立一个由参考数据集、计算技术、分析方法和临床方案组成的综合工具箱。事实证明,这一努力是成功的,因为 2012 年至 2016 年期间,约 75% 的 NIH 微生物组研究资助获得者(研究范围超过 100 种疾病)在其资金申请中依赖 HMP 数据和工具。HMP 由美国国立卫生研究院 (NIH) 资助,大大加速了美国国内和全球的人类微生物组研究。研究活动的增加可能会为市场上创新疗法的开发提供机会。
人类微生物组市场区域洞察
Insight Partners 的分析师详细解释了预测期内影响人类微生物组市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的人类微生物组市场细分和地理位置。
- 获取人类微生物组市场的区域特定数据
人类微生物组市场报告范围
报告属性 | 细节 |
---|---|
2023 年的市场规模 | 10.7亿美元 |
2031 年市场规模 | 48.4 亿美元 |
全球复合年增长率(2023 - 2031) | 20.8% |
史料 | 2021-2022 |
预测期 | 2024-2031 |
涵盖的领域 | 按类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
市场参与者密度:了解其对商业动态的影响
人类微生物组市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求又源于消费者偏好的不断变化、技术进步以及对产品优势的认识不断提高等因素。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者的需求,并利用新兴趋势,从而进一步推动市场增长。
市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。
在人类微生物组市场运营的主要公司有:
- MaaT 制药
- 辉凌控股公司
- 芬奇治疗集团公司
- AOBiome Therapeutics Inc.
- Seres治疗公司
- 默克公司
免责声明:上面列出的公司没有按照任何特定顺序排列。
- 了解人类微生物组市场主要参与者概况
人类微生物组市场新闻和最新发展
通过收集一手和二手研究的定性和定量数据来评估人体微生物组市场,其中包括重要的公司出版物、协会数据和数据库。以下列出了市场中的一些发展情况:
- MaaT Pharma 宣布在欧洲启动一项名为 CHRONOS 的回顾性多中心试验。其目的是为公司提供未接受 MaaT013 或任何微生物组干预的患者的三线疗法疗效数据。该研究不是由监管机构要求的,也不会影响现金预测,因为资金已经到位。(来源:MaaT Pharma,公司网站,2024 年 3 月)。
- Seres Therapeutics, Inc. 已获得美国食品药品监督管理局 (FDA) 批准,根据新药临床试验 (IND) 申请使用 SER-155。SER-155 是一种口服、合理设计、培养的微生物组疗法,旨在降低免疫功能低下患者的胃肠道抗生素耐药性细菌感染、菌血症和移植物抗宿主病 (GvHD) 的发病率。(来源:Seres Therapeutics, Inc,公司网站,2021 年 6 月)
人类微生物组市场报告覆盖范围和交付成果
“人类微生物组市场规模和预测(2021-2031)”报告对以下领域进行了详细的市场分析:
- 范围内涵盖的所有主要细分市场的全球、区域和国家层面的人类微生物组市场规模和预测
- 人类微生物组市场趋势,以及驱动因素、限制因素和关键机遇等市场动态
- 详细的 PEST 和 SWOT 分析
- 人类微生物组市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
- 行业格局和竞争分析,涵盖市场集中度、热图分析、知名参与者以及人类微生物组市场的最新发展
- 详细的公司简介
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
- Virtual Pipeline Systems Market
- HVAC Sensors Market
- Unit Heater Market
- Rare Neurological Disease Treatment Market
- Small Internal Combustion Engine Market
- Flexible Garden Hoses Market
- Rugged Servers Market
- Medical and Research Grade Collagen Market
- Water Pipeline Leak Detection System Market
- Personality Assessment Solution Market
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
North America dominated the market in 2023.
Significant investments by key market players and government initiatives are among the most significant factors fueling the market growth.
The emergence of precision medicine is expected to emerge as a prime trend in the market in the coming years.
MaaT Pharma; Ferring Holdings SA; Finch Therapeutics Group Inc; AOBiome Therapeutics Inc.; Seres Therapeutics Inc; Merck & Co Inc; Yakult Honsha Co., Ltd; Rebiotix; Inc; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc are among the key players in the market.
The human microbiome market value is expected to reach US$ 4.84 billion by 2031.
The market is expected to register a CAGR of 20.8% during 2023–2031.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Human Microbiome Market
- MaaT Pharma
- Ferring Holdings SA
- AOBiome Therapeutics Inc.
- Seres Therapeutics Inc
- Merck & Co Inc
- Yakult Honsha Co., Ltd
- Rebiotix, Inc
- IFF Nutrition & Biosciences,
- Synthetic Biologics, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.